ly3298176 tirzepatide Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Tirzepatide, a dual GIP/GLP-1 receptor
Pay in 4 interest-free payments of $5.93 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24


























![Coat of Arms [Tenth Edition] 22](https://cdn.shopify.com/s/files/1/0617/9821/9946/products/40dfd0bd-464e-593a-8538-0fa8725b8295.jpg?v=1658564939)


